SEATTLE, Nov. 3, 2010 /PRNewswire/ — Cocrystal Discovery, Inc.,
a biopharmaceutical company focused on the discovery and
development of novel antiviral therapeutics for the treatment of
serious and chronic viral diseases, announced today that it has
received $733,438 in grants from the Qualified Therapeutic
Discovery Project (QTDP) administered under section 48D of the
Internal Revenue Code. The QTDP grant program provides
support for innovative projects that are determined by the U.S.
Department of Health and Human Services to have reasonable
potential to result in a new therapy, reduce health care costs, or
significantly advance the goal of curing cancer.
The QTDP grants awarded to Cocrystal are for programs in
hepatitis C, influenza, and the common cold, diseases that
collectively affect billions of people worldwide.
Cocrystal is a biopharmaceutical company dedicated to the
development of small molecule, broad-spectrum antiviral
therapeutics. The Company has laboratories in Bothell, Washington
and Mountain View, California. Cocrystal is a privately held
company with headquarters in Bothell, Washington.
‘/>”/>
